Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) p...

Full description

Bibliographic Details
Main Authors: Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, Antonio Bernardo, Laura Biganzoli, Giancarlo Bisagni, Livio Blasi, Emilio Bria, Francesco Cognetti, Lucio Crinò, Michelino De Laurentiis, Lucia Del Mastro, Sabino De Placido, Alessandra Beano, Francesco Ferraù, Silva Foladore, Rosachiara Forcignanò, Teresa Gamucci, Ornella Garrone, Alessandra Gennari, Monica Giordano, Francesco Giotta, Filippo Giovanardi, Luciano Latini, Lorenzo Livi, Paolo Marchetti, Rodolfo Mattioli, Andrea Michelotti, Filippo Montemurro, Carlo Putzu, Ferdinando Riccardi, Giuseppina Ricciardi, Emanuela Romagnoli, Giuseppina Sarobba, Simon Spazzapan, Pierosandro Tagliaferri, Nicola Tinari, Giuseppe Tonini, Anna Turletti, Claudio Verusio, Alberto Zambelli, Giorgio Mustacchi
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
metastatic breast cancer
HER2 negative
progression free survival
time to treatment change
overall survival
Online Access:https://www.mdpi.com/2072-6694/16/1/117

Internet

https://www.mdpi.com/2072-6694/16/1/117

Similar Items